Lenalidomide in Combination with Rituximab as Treatment for Patients with Relapsed Chronic Lymphocytic Leukemia - RV-CLL-PI-0292.

Trial Profile

Lenalidomide in Combination with Rituximab as Treatment for Patients with Relapsed Chronic Lymphocytic Leukemia - RV-CLL-PI-0292.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2015

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jul 2014 Status changed from active, no longer recruiting to discontinued, as per M.D. Anderson Cancer Center record.
    • 18 Apr 2013 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 16 Dec 2011 Planned end date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top